Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Martin

Showing results (301-310 of 361) with videos related to

Pageof 37
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 15, 2020
Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trialDavid Krug, Reinhard Vonthein, Andreas Schreiber, et al.
European Heart Journal|October 7, 2023
A 20-year population study of peripartum cardiomyopathyAlice M Jackson, Mark Macartney, Katriona Brooksbank, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Science Advances|August 7, 2024
The origins of mammal growth patterns during the Jurassic mammalian radiationElis Newham, Ian J Corfe, Philippa Brewer, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Future Oncology (London, England)|June 27, 2026
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasoneKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
International Journal of Pharmaceutics|May 12, 2025
Bacterial diversity, viability and stability in lyophilised faecal microbiota capsules support ongoing clinical useNur Masirah M Zain, Blair Merrick, Thomas Martin-Lilley, et al.
Journal of Thrombosis and Haemostasis : JTH|June 8, 2021
The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccinationMicol G Cittone, Raphael Battegay, Adalgisa Condoluci, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Pageof 37

Showing results (301-310 of 361) with videos related to

Sort By:
Pageof 37
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 15, 2020
Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trialDavid Krug, Reinhard Vonthein, Andreas Schreiber, et al.
European Heart Journal|October 7, 2023
A 20-year population study of peripartum cardiomyopathyAlice M Jackson, Mark Macartney, Katriona Brooksbank, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Science Advances|August 7, 2024
The origins of mammal growth patterns during the Jurassic mammalian radiationElis Newham, Ian J Corfe, Philippa Brewer, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
Future Oncology (London, England)|June 27, 2026
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasoneKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
International Journal of Pharmaceutics|May 12, 2025
Bacterial diversity, viability and stability in lyophilised faecal microbiota capsules support ongoing clinical useNur Masirah M Zain, Blair Merrick, Thomas Martin-Lilley, et al.
Journal of Thrombosis and Haemostasis : JTH|June 8, 2021
The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccinationMicol G Cittone, Raphael Battegay, Adalgisa Condoluci, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Pageof 37